Five years ago, rival hospital companies in this blue-collar corner of Appalachia made a deal. If state lawmakers let them merge, leaving no competitors, the hospitals promised not to gouge prices or cut corners.
Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights
Why are biotech investors so interested in autoimmune disease? Who is behind the telehealth GLP-1 boom? And what were our favorite moments from the STAT